Title (en)

TREATMENT OF PATHOLOGIES WHICH ESCAPE THE IMMUNE RESPONSE, USING OPTIMISED ANTIBODIES

Title (de)

VERWENDUNG VON OPTIMIERTEN ANTIKÖRPERN ZUR BEHANDLUNG VON KRANKHEITEN, DIE DER IMMUNANTWORT ENTFLIEHEN

Title (fr)

TRAITEMENT DES PATHOLOGIES ECHAPPANT A LA REPONSE IMMUNE PAR DES ANTICORPS OPTIMISES

Publication

EP 1545614 A2 20050629 (FR)

Application

EP 03775438 A 20030915

Priority

- FR 0302714 W 20030915
- FR 0211415 A 20020913
- FR 0211416 A 20020913
- FR 0307066 A 20030612

Abstract (en)

[origin: FR2844455A1] Use of an optimized chimeric humanized or human monoclonal antibody (MAb) to produce a composition for treating disease in which: (a) the number of antigen sites (antigenic density) is low or the antigens are poorly accessible to antibodies; or (b) the number of effector cells (EC) activated or recruited is low. Use of an optimized chimeric humanized or human monoclonal antibody (MAb) to produce a composition for treating disease in which: (a) the number of antigen sites (antigenic density) is low or the antigens are poorly accessible to antibodies; or (b) the number of effector cells (EC) activated or recruited is low. MAb has a glycan structure generally of the 'two-antennae' type, with short chains, low level of silylation of mannose and GlcNAc at the non-intercalated terminal points of attachment, low level of fucosylation and non-zero level of intermediate GlcNAc.

IPC 1-7

A61K 39/395; A61P 35/00; A61P 33/00; A61P 31/00; C07K 16/00

IPC 8 full level

A61K 39/395 (2006.01); **A61P 7/00** (2006.01); **A61P 31/00** (2006.01); **A61P 33/00** (2006.01); **A61P 35/00** (2006.01); **C07K 16/00** (2006.01); **C07K 16/28** (2006.01); **C07K 16/34** (2006.01)

CPC (source: EP US)

A61P 3/00 (2017.12 - EP); **A61P 7/00** (2017.12 - EP); **A61P 7/04** (2017.12 - EP); **A61P 7/06** (2017.12 - EP); **A61P 17/00** (2017.12 - EP); **A61P 31/00** (2017.12 - EP); **A61P 31/06** (2017.12 - EP); **A61P 33/00** (2017.12 - EP); **A61P 33/12** (2017.12 - EP); **A61P 35/00** (2017.12 - EP); **A61P 35/02** (2017.12 - EP); **A61P 37/04** (2017.12 - EP); **A61P 43/00** (2017.12 - EP); **C07K 16/2833** (2013.01 - EP US); **C07K 16/2896** (2013.01 - EP US); **C07K 16/34** (2013.01 - EP US); C07K 2317/732 (2013.01 - EP US)

Citation (search report)

See references of WO 2004028564A2

Citation (examination)

- EP 1176195 A1 20020130 - KYOWA HAKKO KOGYO KK [JP]
- SHINKAWA T ET AL: "The absence of fucose but not the presence of galactose or bisecting N-acetylglucosamine of human IgG1 complex-type oligosaccharides shows the critical role of enhancing antibody-dependent cellular cytotoxicity", JOURNAL OF BIOLOGICAL CHEMISTRY, THE AMERICAN SOCIETY OF BIOLOGICAL CHEMISTS, INC., BALTIMORE, MD, US, vol. 278, no. 5, 31 January 2003 (2003-01-31), pages 3466 - 3473, XP002965857, ISSN: 0021-9258, DOI: DOI:10.1074/JBC.M210665200
- DAVIES J ET AL: "Expression of GnTIII in a recombinant anti-CD20 CHO production cell line: Expression of antibodies with altered glycoforms leads to an increase in ADCC through higher affinity for FC gamma RIII", BIOTECHNOLOGY AND BIOENGINEERING - COMBINATORIAL CHEMISTRY, WILEY, NEW YORK, NY, US, vol. 74, no. 4, 20 August 2001 (2001-08-20), pages 288 - 294, XP002285964, DOI: DOI:10.1002/BIT.1119

Designated contracting state (EPC)

AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PT RO SE SI SK TR

DOCDB simple family (publication)

FR 2844455 A1 20040319; **FR 2844455 B1 20071214**; AU 2003283469 A1 20040419; AU 2003283469 B2 20091224; AU 2003283469 C1 20100520; CA 2498383 A1 20040408; CA 2498383 C 20150428; EP 1545614 A2 20050629; EP 3001198 A1 20160330; IL 167381 A 20140130; IL 230101 A0 20140130; IL 230101 A 20160531; JP 2006504700 A 20060209; JP 2010006824 A 20100114; JP 2014065735 A 20140417; JP 5951923 B2 20160713; JP 6238743 B2 20171129; US 2005271652 A1 20051208; US 2009081216 A1 20090326; WO 2004028564 A2 20040408; WO 2004028564 A3 20040930; WO 2004028564 A8 20050623

DOCDB simple family (application)

FR 0307066 A 20030612; AU 2003283469 A 20030915; CA 2498383 A 20030915; EP 03775438 A 20030915; EP 15182965 A 20030915; FR 0302714 W 20030915; IL 16738105 A 20050310; IL 23010113 A 20131223; JP 2004539110 A 20030915; JP 2009190989 A 20090820; JP 2013272030 A 20131227; US 23460908 A 20080919; US 52766605 A 20050801